Morgan Stanley grew its stake in shares of Sierra Oncology Inc (NASDAQ:SRRA) by 11.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 992,516 shares of the biotechnology company’s stock after buying an additional 100,709 shares during the quarter. Morgan Stanley owned 1.33% of Sierra Oncology worth $1,687,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Prosight Management LP lifted its holdings in Sierra Oncology by 50.6% in the 3rd quarter. Prosight Management LP now owns 2,720,089 shares of the biotechnology company’s stock worth $4,624,000 after purchasing an additional 913,527 shares during the last quarter. Algert Global LLC lifted its holdings in Sierra Oncology by 173.8% in the 3rd quarter. Algert Global LLC now owns 394,258 shares of the biotechnology company’s stock worth $670,000 after purchasing an additional 250,267 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Sierra Oncology by 27.5% in the 3rd quarter. Renaissance Technologies LLC now owns 2,252,244 shares of the biotechnology company’s stock worth $3,829,000 after purchasing an additional 485,344 shares during the last quarter. Citadel Advisors LLC lifted its holdings in Sierra Oncology by 42.7% in the 3rd quarter. Citadel Advisors LLC now owns 1,832,042 shares of the biotechnology company’s stock worth $3,114,000 after purchasing an additional 548,591 shares during the last quarter. Finally, Bridgeway Capital Management Inc. lifted its holdings in Sierra Oncology by 36.9% in the 3rd quarter. Bridgeway Capital Management Inc. now owns 225,000 shares of the biotechnology company’s stock worth $383,000 after purchasing an additional 60,700 shares during the last quarter. 65.25% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NASDAQ SRRA opened at $1.86 on Friday. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $141.49 million, a price-to-earnings ratio of -2.48 and a beta of 1.80. Sierra Oncology Inc has a 12 month low of $1.05 and a 12 month high of $3.70.

Sierra Oncology (NASDAQ:SRRA) last issued its quarterly earnings results on Thursday, February 28th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.01. On average, research analysts forecast that Sierra Oncology Inc will post -0.9 earnings per share for the current fiscal year.

Separately, Wedbush restated an “outperform” rating on shares of Sierra Oncology in a report on Thursday, February 28th.

TRADEMARK VIOLATION NOTICE: “Sierra Oncology Inc (SRRA) Shares Bought by Morgan Stanley” was reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dailypolitical.com/2019/03/16/sierra-oncology-inc-srra-shares-bought-by-morgan-stanley.html.

Sierra Oncology Profile

Sierra Oncology, Inc, a clinical stage drug development company, researches, develops, and commercializes DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer in the United States and internationally. The company's lead drug candidate is SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, which is in Phase 1 clinical trial to treat patients with advanced cancer.

See Also: Hedge Funds – Risk or Reward?

Want to see what other hedge funds are holding SRRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sierra Oncology Inc (NASDAQ:SRRA).

Institutional Ownership by Quarter for Sierra Oncology (NASDAQ:SRRA)

Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.